개요
The Immune Shield stack combines the most clinically validated immune-enhancing peptide with a systemic repair compound to create a foundational immune optimization protocol. Thymosin Alpha-1 (Ta1) is a 28-amino-acid peptide that was originally isolated from thymic extract (Thymosin Fraction 5) by Allan Goldstein at George Washington University. It functions as the primary signal for T-cell maturation and activation — without adequate thymic output, the adaptive immune system cannot mount effective responses to novel pathogens or maintain immune surveillance against malignant cells. Ta1 is approved in 35+ countries (as Zadaxin) for hepatitis B, hepatitis C, and as a vaccine adjuvant, with over 4,400 published clinical papers documenting its efficacy and safety. BPC-157 is included for its unique influence on the gut-immune axis. Approximately 70% of immune tissue resides in the gut-associated lymphoid tissue (GALT), and intestinal barrier integrity directly influences systemic immune function. BPC-157''s documented effects on tight junction repair, mucosal healing, and modulation of the enteric nervous system support immune function at its largest interface with the external environment. Additionally, BPC-157''s anti-inflammatory properties help redirect immune resources from chronic low-grade inflammation toward active immune surveillance. The combination addresses immune health from two levels: Ta1 provides direct immune cell activation and maturation (top-down immune enhancement), while BPC-157 optimizes the mucosal barrier and gut immune environment that serves as the foundation of immune competence (bottom-up immune support). This stack is classified as beginner-friendly because both peptides have extensive safety data (Ta1 from international clinical use, BPC-157 from decades of animal research), the dosing schedule is simple, and there are no significant drug interactions or monitoring requirements. It is suitable for seasonal immune support, travel prophylaxis, or as a foundation for individuals with recurrent infections.
용량 프로토콜
1,500 mcg
1회 용량당
250 mcg
1회 용량당
목표 및 증거
경고
- Thymosin Alpha-1 remains FDA Category 2 (restricted) in the US (approved abroad in 35+ countries as Zadaxin). BPC-157 was removed from FDA Category 2 (April 2026) but remains under PCAC review — not legal to compound yet. Good safety profile in clinical literature.
Comments
Sign in to join the discussion
주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.